Patents by Inventor Maria Angeles Martinez-Grau

Maria Angeles Martinez-Grau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ghrelin 0-acyl transferase inhibitors
    Patent number: 10227310
    Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: March 12, 2019
    Assignee: Eli Lilly and Company
    Inventors: Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza, Almudena Rubio, Stacy Jo Keding, Daryl Lynn Smith
  • Ghrelin O-acyl transferase inhibitors
    Patent number: 10093651
    Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: October 9, 2018
    Assignee: Eli Lilly and Company
    Inventors: Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza, Almudena Rubio
  • GHRELIN 0-ACYL TRANSFERASE INHIBITORS
    Publication number: 20180086732
    Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
    Type: Application
    Filed: April 13, 2016
    Publication date: March 29, 2018
    Inventors: Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza, Almudena Rubio
  • GHRELIN 0-ACYL TRANSFERASE INHIBITORS
    Publication number: 20180079729
    Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
    Type: Application
    Filed: April 13, 2016
    Publication date: March 22, 2018
    Inventors: Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza, Almudena Rubio, Stacy Jo Keding, Daryl Lynn Smith
  • 2-oxo-1,3,8-triazaspiro[4.5]decan-3-yl] carboxylic acid derivatives
    Patent number: 9920056
    Abstract: The present invention provides compounds of Formula 1, where A is selected from and R1, R2 and R3 are defined in the specification, or a pharmaceutically acceptable salt thereof, methods of using the compounds to treat diabetes, and processes for the synthesis of the compounds.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: March 20, 2018
    Assignee: Eli Lilly and Company
    Inventors: Thomas James Beauchamp, David Andrew Coates, Maria Angeles Martinez-Grau, Miguel Angel Toledo
  • 2-OXO-1,3,8-TRIAZASPIRO[4.5]DECAN-3-YL] CARBOXYLIC ACID DERIVATIVES
    Publication number: 20160368922
    Abstract: The present invention provides compounds of Formula 1, where A is selected from and R1, R2 and R3 are defined in the specification, or a pharmaceutically acceptable salt thereof, methods of using the compounds to treat diabetes, and processes for the synthesis of the compounds.
    Type: Application
    Filed: June 8, 2016
    Publication date: December 22, 2016
    Inventors: Thomas James Beauchamp, David Andrew Coates, Maria Angeles Martinez-Grau, Miguel Angel Toledo
  • Ghrelin O-acyl transferase inhibitor
    Patent number: 9035051
    Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: May 19, 2015
    Assignee: Eli Lilly and Company
    Inventor: Maria Angeles Martinez-Grau
  • GHRELIN O-ACYL TRANSFERASE INHIBITOR
    Publication number: 20150133474
    Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 14, 2015
    Inventor: Maria Angeles Martinez-Grau
  • 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonists
    Patent number: 8680091
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: March 25, 2014
    Assignee: Eli Lilly and Company
    Inventors: Karen Briner, Manuel Javier Cases-Thomas, Marta Adeva Bartolome, Christopher Stanley Galka, Alicia Marcos Llorente, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, John Cunningham O'Toole, Richard Edmund Rathmell, Matthew Robert Reinhard, Selma Sapmaz, Andrew Caerwyn Williams
  • 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonist
    Patent number: 8580780
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: November 12, 2013
    Assignee: Eli Lilly and Company
    Inventors: John Gordon Allen, Karin Briner, Christopher Stanley Galka, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothhaar, Michael Wade Tidwell, Frantz Victor, Deyi Zhang, Steven Armen Boyd, Arundhati S. Deo, Wai-Man Lee, Christopher Stephen Siedem, Ajay Singh
  • 6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonists
    Patent number: 8420631
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where R6 is —C?C—R10, —CH?CR11R11?, or —(C0-C8)alkyl-Ar2 optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents and other substituents are as defined in the specification.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: April 16, 2013
    Assignee: Eli Lilly and Company
    Inventors: John Gordon Allen, Karin Briner, Anne Marie Camp, Manuel Javier Cases-Thomas, Richard Charles Hoying, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, Natalia Pokrovskaia, Richard Edmund Rathmell, Roger Ryan Rothhaar, Selma Sapmaz, Andrew Caerwyn Williams
  • SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS
    Publication number: 20120214784
    Abstract: An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraines.
    Type: Application
    Filed: November 12, 2010
    Publication date: August 23, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Ana Belen Benito Collado, Nuria Diaz Buezo, Alma Maria Jimenez-Aguado, Celia Lafuente Blanco, Maria Angeles Martinez-Grau, Concepcion Pedregal Tercero, Miguel Angel Toledo Escribano
  • Spiropiperidine compounds as ORL-1 receptor antagonists
    Patent number: 8232289
    Abstract: An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: July 31, 2012
    Assignee: Eli Lilly and Company
    Inventors: Ana Belen Benito Collado, Nuria Diaz Buezo, Alma Maria Jimenez-Aguado, Celia Lafuente Blanco, Maria Angeles Martinez-Grau, Concepcion Pedregal-Tercero, Miguel Angel Toledo Escribano
  • 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist
    Publication number: 20120028961
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.
    Type: Application
    Filed: July 28, 2011
    Publication date: February 2, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: JOHN GORDON ALLEN, Karin Briner, Michael Philip Cohen, Christopher Stanley Galka, Sarah Lynne Hellman, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothhaar, Michael Wade Tidwell, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang, Steven Armen Boyd, Richard Gerard Conway, Arundhati S. Deo, Wai-Man Lee, Christopher Stephen Siedem, Ajay Singh, Michael Philip MAZANETZ
  • 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
    Publication number: 20110269745
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.
    Type: Application
    Filed: June 9, 2011
    Publication date: November 3, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Karin BRINER, Marta ADEVA BARTOLOME, Manuel Javier CASES-THOMAS, Christopher Stanley GALKA, Alicia MARCOS LLORENTE, Maria Angeles MARTINEZ-GRAU, Michael Philip MAZANETZ, John Cunningham O'Toole, Richard Edmund RATHMELL, Matthew Robert REINHARD, Selma SAPMAZ, Andrew Caerwyn WILLIAMS
  • 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonists
    Patent number: 8022062
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —C?C—R10, —O—R12, —S—R14, or —NR24R25; and other substituents are as defined in the specification.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: September 20, 2011
    Assignee: Eli Lilly and Company
    Inventors: John Gordon Allen, Karin Briner, Michael Philip Cohen, Christopher Stanley Galka, Sarah Lynne Hellman, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothhaar, Michael Wade Tidwell, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang, Michael Philip Mazanetz
  • 6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonists
    Patent number: 7994163
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R?N—R?R* where R6 is —(CrC3)alkyl-S—(C0-C3)alkyl-R10, —(C1-C3)alkyl-NR11R12, —(CrC3)alkyl-O—R13. and other substituents are as defined in the specification.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: August 9, 2011
    Assignee: Eli Lilly and Company
    Inventors: John Gordon Allen, Karin Briner, Christopher Stanley Galka, Richard Charles Hoying, Maria Angeles Martinez-Grau, Julie Miyashiro, Natalia Pokrovskaia, Matthew Robert Reinhard
  • SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS
    Publication number: 20110118251
    Abstract: An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Application
    Filed: November 10, 2010
    Publication date: May 19, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Ana Belen BENITO COLLADO, Nuria DIAZ BUEZO, Alma Maria JIMENEZ-AGUADO, Celia LAFUENTE BLANCO, Maria Angeles MARTINEZ-GRAU, Concepcion PEDREGAL-TERCERO, Miguel Angel TOLEDO ESCRIBANO
  • 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
    Publication number: 20090099155
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzoazepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is -C?C-R10, -O-R12, -S-R14, or -NR24R25; and other substituents are as defined in the specification.
    Type: Application
    Filed: September 9, 2005
    Publication date: April 16, 2009
    Inventors: John Gordon Allen, Karin Briner, Michael Philip Cohen, Christopher Stanley Galka, Sarah Lynne Hellman, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothaar, Michael Wade Tidwell, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang, Steven Armen Boyd, Richard Gerard Conway, Arundhati S. Deo, Wai-Man Lee, Christopher Stephen Siedem, Ajay Singh, Michael Philip Mazanetz
  • 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists
    Publication number: 20080269196
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.
    Type: Application
    Filed: September 1, 2006
    Publication date: October 30, 2008
    Inventors: Karin Briner, Maria Adeva Bartolome, Manuel Javier Cases-Thomas, Christopher Stanley Galka, Alicia Marcos Llorente, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, John Cunningham O' Toole, Richard Edmund Rathmell, Matthew Robert Reinhard, Selma Sapmaz, Andrew Caerwyn Williams